What are Roivant Sciences's total assets?

Roivant Sciences (ROIV) holds $5.7B in total assets, up 5.0% year over year.

How much debt does Roivant Sciences have?

Roivant Sciences carries $107.4M in total debt against $4.5B of shareholders' equity, a debt-to-equity ratio of 0.02.

How much cash does Roivant Sciences have?

Roivant Sciences holds $1.4B in cash and equivalents.

Can Roivant Sciences cover its short-term obligations?

Its current ratio is 18.37 — current assets exceed current liabilities.

Where does Roivant Sciences's balance sheet data come from?

Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Roivant Sciences ROIV Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$1.42B+1,411%	$93.95M-48.6%	$182.67M-89.2%	$1.69B-18.4%
Short-term investments	$2.87B+32.3%	$2.17B—	$0—	——
Restricted cash	——	$2.36M-23.1%	$3.07M-38.8%	$5.01M+28.4%
Prepaid expenses and other current assets	$105.32M-6.9%	$113.17M+40.4%	$80.61M-33.8%	$121.77M+41.4%
Derivative assets	——	$9.98M—	——	——
Total current assets	$5.17B+3.3%	$5B-25.7%	$6.73B+274%	$1.8B-16.2%
Property and equipment, net	$11.99M-0.6%	$12.06M-21.3%	$15.32M-60.8%	$39.09M+50.9%
Operating lease right-of-use assets	$80.42M-9.7%	$89.02M+102%	$44M-17.4%	$53.25M-12.8%
Other non-current assets	$40.92M+24.5%	$32.86M-12.8%	$37.7M-23.8%	$49.48M+91.6%
Total investment securities	$407.99M+34.7%	$302.94M+22.3%	$247.75M-18.6%	$304.32M-6.6%
Total assets	$5.71B+5.0%	$5.44B-24.7%	$7.22B+202%	$2.39B-7.6%
Accounts payable	$18M-24.0%	$23.69M+68.9%	$14.03M-62.9%	$37.83M+9.4%
Accrued expenses	$583K-50.1%	$1.17M-91.6%	$13.94M-7.5%	$15.08M+38.9%
Deferred revenue	——	$1.17M-72.0%	$4.17M-66.5%	$12.44M+22.6%
Operating lease liabilities, current	$11.15M+13.3%	$9.84M+9.8%	$8.97M-23.3%	$11.69M+2.6%
Income taxes payable	$45.69M+10,883%	$416K-95.7%	$9.77M+1,703%	$542K-23.4%
Other current liabilities	——	$0—	$0-100%	$2.09M—
Total current liabilities	$281.24M+88.2%	$149.41M-44.0%	$266.76M-2.1%	$272.45M+47.8%
Operating lease liabilities, non-current	$96.29M+6.6%	$90.33M+101%	$45.02M-15.8%	$53.48M-14.4%
Operating Lease Liabilities (Total)	$107.44M+7.3%	$100.17M+75.3%	$57.16M-12.3%	$65.17M-11.8%
Other non-current liabilities	$70K+218%	$22K-99.1%	$2.49M-85.4%	$17.03M-22.3%
Total liabilities	$416.28M+66.7%	$249.74M-67.7%	$773.95M-1.0%	$782.02M+49.3%
Common stock	$0—	$0—	$0—	$0—
Additional paid-in capital	$5.02B+10.1%	$4.56B-15.5%	$5.4B+9.4%	$4.93B+11.6%
Retained earnings	-$501.81M-532%	$116.06M-79.9%	$576.17M+115%	-$3.77B-36.5%
Accumulated other comprehensive income (loss)	$4.36M-53.8%	$9.44M+331%	-$4.08M-56.0%	-$2.62M-177%
Noncontrolling interests	$765.04M+53.1%	$499.59M+4.1%	$479.95M+6.7%	$449.82M+17.8%
Total stockholders' equity	$4.53B-3.4%	$4.69B-21.5%	$5.97B+416%	$1.16B-30.1%
Total liabilities and stockholders' equity	$5.71B+5.0%	$5.44B-24.7%	$7.22B+202%	$2.39B-7.6%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	——	$2.73B-58.4%	$6.55B+287%	$1.69B—
Cash Cash Equivalents And Short Term Investments	——	$4.89B-24.8%	$6.49B—	——
Litigation settlement receivable	$770.24M—	$0—	——	——
Short- term Investments	$2.87B+32.3%	$2.17B—	$0—	——
Other current assets	$105.32M-6.9%	$113.17M+40.4%	$80.61M-33.8%	$121.77M+41.4%
Deferred Tax Assets and Other Non-Current Assets	$40.92M+24.5%	$32.86M-12.8%	$37.7M-23.8%	$49.48M+91.6%
Net Investment in Lease	$80.42M-9.7%	$89.02M+102%	$44M-17.4%	$53.25M-12.8%
Operating lease right-of-use assets	$80.42M-9.7%	$89.02M+102%	$44M-17.4%	$53.25M-12.8%
Other non-current assets	$40.92M+24.5%	$32.86M-12.8%	$37.7M-23.8%	$49.48M+91.6%
Operating Lease Right-of-Use Assets in Other Assets	$80.42M-9.7%	$89.02M+102%	$44M-17.4%	$53.25M-12.8%
Software and Technology Licenses, Net	$40.92M+24.5%	$32.86M-12.8%	$37.7M-23.8%	$49.48M+91.6%
Accrued Manufacturing Costs	——	$53.93M+8.1%	$49.89M-9.6%	$55.19M+24.7%
Other Commercial Liabilities	$205.82M+80.1%	$114.29M-4.3%	$119.42M-28.5%	$167.13M+31.0%
Accrued Liabilities, Current	$205.82M+80.1%	$114.29M-4.3%	$119.42M-28.5%	$167.13M+31.0%
Deferred income	——	$1.17M-72.0%	$4.17M-66.5%	$12.44M+22.6%
Compensation and benefits	——	$53.93M+8.1%	$49.89M-9.6%	$55.19M+24.7%
Other accrued liabilities	$583K-50.1%	$1.17M-91.6%	$13.94M-7.5%	$15.08M+38.9%
Derivative Liabilities - Fair Value	——	$9.98M—	——	——
Debt Maturity - 2025	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Common Stock Par Value Per Share	——	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	——	695.9M-13.7%	806.7M+6.1%	760.1M+9.4%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0—	$0—	$0—	$0—
Share-Based Payment - Nonvested Awards (Number)	——	348.5K—	——	——
Gross Assets/Liabilities	——	$9.98M—	——	——
Research and development expenses	——	$45.81M+21.5%	$37.71M-50.6%	$76.28M+15.2%
Cash and cash equivalents, end of period	——	$2.73B-58.4%	$6.55B+287%	$1.69B—
Common stock, par value (in dollars per share)	——	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	——	$7B0.0%	$7B0.0%	$7B0.0%
Common stock, shares issued (in shares)	——	$695.94M-13.7%	$806.68M+6.1%	$760.14M+9.4%
Common Stock, Shares, Outstanding	——	$695.94M-13.7%	$806.68M+6.1%	$760.14M+9.4%
Derivative Liability	——	$9.98M—	——	——
Investments Fair Value Disclosure	$407.99M+34.7%	$302.94M+22.3%	$247.75M-18.6%	$304.32M-6.6%
Lessee Operating Lease Discount Rate	——	——	——	——
Liability instruments measured at fair value	$0-100%	$9.98M-61.2%	$25.74M-59.5%	$63.55M+41.5%
Milestone receivable from sale of discontinued operations	——	——	——	——
Noncontrolling interests in subsidiaries	$765.04M+53.1%	$499.59M+4.1%	$479.95M+6.7%	$449.82M+17.8%
Money Market Funds At Carrying Value	——	$2.62B-58.5%	$6.31B—	——
Other accrued liabilities	——	$14.55M-54.3%	$31.82M+75.8%	$18.1M+5.9%
Other	——	$0—	$0-100%	$2.09M—
Purchase Obligation	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number	——	$348.53K—	——	——
Income tax payable, noncurrent	$38.67M—	$0—	——	——
Purchase Commitments - Due Next Year	——	——	——	——
Purchase Obligation	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——
Weighted-Average Discount Rate	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Roivant Sciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Roivant Sciences's total assets?: Roivant Sciences (ROIV) holds $5.7B in total assets, up 5.0% year over year.
How much debt does Roivant Sciences have?: Roivant Sciences carries $107.4M in total debt against $4.5B of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Roivant Sciences have?: Roivant Sciences holds $1.4B in cash and equivalents.
Can Roivant Sciences cover its short-term obligations?: Its current ratio is 18.37 — current assets exceed current liabilities.
Where does Roivant Sciences's balance sheet data come from?: Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.